We invest in innovative products addressing unmet needs.
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.Visit Allogene.com
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model. Hubble is making daily disposable lenses affordable and convenient - important because daily disposable lenses are widely acknowledged as better for health and comfort. With Hubble, consumers don't have to choose anymore between overpaying and over wearing their lenses.Visit HubbleContacts.com
Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs.Visit Breakthrough Properties
Kite, a Gilead company, is a leader in developing and commercializing autologous chimeric antigen receptor T-cell (CAR T) and T cell receptor (TCR) therapies for the treatment of cancer. In 2017, Kite received approval for Yescarta™, the first FDA approved CAR T therapy for the treatment of adult patients with certain types of large B-cell lymphoma. Kite was acquired by Gilead in 2017 for $11.9 billion.Visit Kitepharma.com
Cell Design Labs
Cell Design Labs is a private biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability.Visit Celldesignlabs.com
UroGen Pharma (NASDAQ: URGN) is a clinical-stage biopharmaceutical company focused on developing novel therapies with a focus on uro-oncology. UroGen’s lead drug candidates are designed to change the standard of care for urological pathologies by potentially removing tumors by non-surgical means.Visit Urogen.com
Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.Visit KronosBio.com
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. is a biomedical company dedicated to developing next-generation T cell therapies that target mutated proteins (neo-antigens) in cancer. Neogene is developing a minimally invasive and scalable platform that will enable targeting of neo-antigens occurring in individual patients with fully personalized and genetically engineered “Designer T cells” that have been optimized to seek and destroy tumor cells based on neo-antigens.Visit Neogene